FDA/EC/EMEA joint inspections
Executive Summary
FDA has agreed to collaborate with the European Commission and European Medicines Agency on pilot projects involving joint inspections of pharmaceutical manufacturers in the U.S. and EU and of manufacturers of active pharmaceutical ingredients in "third" countries, the Transatlantic Economic Council announced at a May 13 meeting in Brussels. The organizations will also pilot the exchange of inspection results to better identify API manufacturers in third countries and will accelerate efforts to determine "to what extent dedicated production facilities are necessary for certain pharmaceuticals," according to a TEC summary. Formed in 2007, the TEC is designed to foster closer economic standards by harmonizing standards and is comprised of U.S. Cabinet members and European commissioners
You may also be interested in...
CBER To Train Foreign Regulators On Biologics Review
October seminar is planned in response to international requests; CDER will hold companion forum.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.